Clinical Trial Update: Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers [Phase 1, Phase 2]

View source ↗

Summary

An NCI-sponsored Phase 1/2 study evaluated the combination of imatinib mesylate and bevacizumab in advanced melanoma and other solid tumors, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage III Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-01-16